DUBLIN--(BUSINESS WIRE)--The "Investigation Report on Chinese Thymosin a1 Market, 2018-2022" report has been added to ResearchAndMarkets.com's offering.
According to the report, Thymosin 1 has been growing since it entered China, with its sales value increasing from less than CNY 7 million in 2015 to more than CNY 1.2 billion in 2017.
The Chinese Thymosin 1 market is now dominated by the products of Patheon, Hainan Shuangcheng Pharmaceuticals Co., Ltd., Chengdu DIAO Jiuhong Pharmaceutical Factory, etc.
By sales value, Patheon captured more than half of the market, becoming the most powerful market player in 2017. By sales volume, Chengdu DIAO Jiuhong Pharmaceutical Factory took up the largest market share. Many domestic enterprises seek to scrabble for market shares from Patheon by the advantage of low prices.
According to research, the incidence of cancer is increasing with economic development, aggravating environmental pollution and residents' changing lifestyle; therefore, the Thymosin 1 market will continue to grow from 2018 to 2022 as the immunomodulator market grows gradually.
- Patheon N.V.
- Chengdu DIAO Jiuhong Pharmaceutical Factory
Hainan Shuangcheng Pharmaceuticals
Hainan Zhonghe Pharmaceutical
SPH No. 1 Biochemical & Pharmaceutical
Suzhou Tianma Pharma Group Tianji Bio-Pharmaceutical
Chengdu Shengnuo Biopharm
Harbin Pharmaceutical Group Bio-Engineering
- Size of Chinese Thymosin 1 market
- Competition pattern of the Chinese Thymosin 1 market
Key Topics Covered
1 Relevant Concepts of Thymosin 1
2 Investigation on Sales of Thymosin 1 in China, 2013-2017
3 Market Shares of Major Thymosin 1 Manufacturers in China
4 Prices of Thymosin 1 in China, 2017-2018
5 Prospects of Chinese Thymosin 1 arket, 2018-2022
For more information about this report visit https://www.researchandmarkets.com/research/xn3j9x/the_thymosin_a1?w=4